Reckitt Benckiser Group (RB) Receives “Buy” Rating from Morgan Stanley
RB has been the subject of several other reports. Barclays reissued an equal weight rating and issued a GBX 6,450 ($84.28) target price on shares of Reckitt Benckiser Group in a research report on Tuesday, September 4th. Credit Suisse Group reissued an underperform rating on shares of Reckitt Benckiser Group in a research report on Thursday, August 23rd. Goldman Sachs Group set a GBX 7,025 ($91.79) target price on shares of Reckitt Benckiser Group and gave the stock a neutral rating in a research report on Monday, October 8th. JPMorgan Chase & Co. boosted their target price on shares of Reckitt Benckiser Group from GBX 7,000 ($91.47) to GBX 9,000 ($117.60) and gave the stock an overweight rating in a research report on Thursday, September 6th. Finally, UBS Group boosted their price objective on shares of Reckitt Benckiser Group from GBX 6,000 ($78.40) to GBX 6,400 ($83.63) and gave the stock a neutral rating in a research note on Monday, September 17th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of GBX 7,021.25 ($91.75).
RB stock opened at GBX 6,714 ($87.73) on Tuesday. Reckitt Benckiser Group has a 12 month low of GBX 5,562 ($72.68) and a 12 month high of GBX 8,110.43 ($105.98).
Reckitt Benckiser Group Company Profile
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.